文献速递血栓与止血

两种美国医疗系统中癌症相关血栓形成临床风险评估模型的推导与验证

Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems.
PubMed 文献 · J Clin Oncol · 2023-01-10

本研究利用2011-2020年诊断的癌症患者回顾性数据,在哈里斯健康系统(HHS,n=9769)推导简易风险评估模型(RAM),并在退伍军人事务部(VA)医疗系统(n=79517)外部验证。新模型6个月VTE累积发生率在高危组为8%-10%、PE/LE-DVT为7%,低危组分别为3%和2%,区分度优于Khorana评分。

要点

  • 新RAM在HHS的c统计量为0.71,在VA为0.68,均优于Khorana评分的0.65和0.60。
  • 新RAM将28%的患者重新分类,验证集中高危组VTE占比从37%提高至68%。
  • 高危组6个月VTE累积发生率为8%-10%,PE/LE-DVT为7%,低危组分别为3%和2%。

核心结论

  • 新RAM将癌症患者分层为高危组(6个月VTE累积发生率8%-10%,PE/LE-DVT 7%)和低危组(分别为3%和2%),性能优于原始Khorana评分,并使高危层VTE事件数翻倍。
  • 作者鼓励通过前瞻性研究进行额外外部验证。

研究设计与样本

  • 回顾性数据研究,使用2011-2020年诊断的癌症患者数据,在哈里斯健康系统(HHS,n=9769)通过LASSO回归推导简易风险评估模型(RAM),并在退伍军人事务部(VA)医疗系统(n=79517)进行外部验证。

主要发现

  • HHS中6个月发生VTE 590例(6.2%)、PE/LE-DVT 437例(4.6%);VA中分别为4027例(5.1%)和3331例(4.2%)。
  • 新RAM包含Khorana评分的组分以及修改的癌症亚型、癌症分期、全身治疗类别、VTE史、瘫痪/制动史、近期住院和亚洲/太平洋岛民种族。
  • c统计量在HHS为0.71、在VA为0.68,而Khorana评分分别为0.65和0.60。
  • 新RAM将28%的患者重新分类,验证数据集中高危组VTE占比从37%提高至68%。
  • 高危组6个月VTE累积发生率为8%-10%、PE/LE-DVT为7%,低危组分别为3%和2%。

局限性

  • 作者鼓励通过前瞻性研究进行额外外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy. METHODS: Using retrospective data from patients diagnosed with incident cancer from 2011-2020, we derived a parsimonious risk assessment model (RAM) using least absolute shrinkage and selection operator regression from the Harris Health System (HHS, n = 9,769) and externally validated it using the Veterans Affairs (VA) health care system (n = 79,517). Bootstrapped c statistics and calibration curves were used to assess external model discrimination and fit. Dichotomized risk strata using integer scores were created and compared against the Khorana score (KS). RESULTS: Incident VTE and PE/LE-DVT at 6 months occurred in 590 (6.2%) and 437 (4.6%) patients in HHS and 4,027 (5.1%) and 3,331 (4.2%) patients in the VA health care system. Assessed at the time of systemic therapy initiation, the new RAM included components of the KS with the modified cancer subtype, cancer staging, systemic therapy class, history of VTE, history of paralysis/immobility, recent hospitalization, and Asian/Pacific Islander race. The c statistic was 0.71 in HHS and 0.68 in the VA health care system (compared with 0.65 and 0.60, respectively, for KS). Furthermore, the new RAM appropriately reclassified 28% of patients and increased the proportion of VTEs in the high-risk group from 37% to 68% in the validation data set. CONCLUSION: The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months (v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies.[Media: see text].

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li A, La J, May SB, et al. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023. PMID: 36626707. doi:10.1200/JCO.22.01542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。